Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/22/2020 10:10 PDT] Cocrystal Pharma, Inc. (NASDAQ:COCP), Up By 100.00% ($0.79) From $0.790 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/14/2020 21:16 PDT] Market Maker Surveillance Report. COCP, Winning Stocks With Lowest Price Friction For Tuesday, April 14th 2020
• [04/13/2020 08:10 PDT] COCP Expected to Trade Up After Bullish Patterns Develop